Most sources consider that mothers receiving antineoplastic therapy should not breastfeed, especially with alkylating agents such as oxaliplatin.[1] In one patient, platinum was found in breastmilk for at least 65 days after her last dose. The exact form and toxicity of platinum that might be excreted into breastmilk are not known. The nursing infant would receive any platinum compounds orally rather than intravenously and oral absorption of oral platinum compounds by infants is not known. Chemotherapy may adversely affect the normal microbiome and chemical makeup of breastmilk.[2] Women who receive chemotherapy during pregnancy are more likely to have difficulty nursing their infant. The manufacturer recommends that women should not breastfeed during treatment with oxaliplatin injection and for 3 months after the final dose, which is consistent with findings of platinum in the milk of one patient.